(+)-JQ1

Catalog No.S7110

(+)-JQ1 Chemical Structure

Molecular Weight(MW): 456.99

(+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2) in cell-free assays, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family.

Size Price Stock Quantity  
USD 270 In stock
USD 570 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

7 Customer Reviews

  • The BET protein inhibitor JQ1 reduces c-Myc expression and attenuates primary MCC cell proliferation. A, decreased c-Myc expression in MCC-3 and MCC-5 treated with JQ1 (800 nmol/L) for 72 hours by qRT-PCR and immunoblotting. The mRNA expression of target genes was normalized to that of MRPS2 and a value of 1.0 was assigned to the mRNA expression of target genes in the control group (means+SEM; **, P < 0.01 vs. control); b-actin was used as a loading control for immunoblotting.

    Cancer Res 2014 74(23), 7090-102. (+)-JQ1 purchased from Selleck.

    Immunohistochemical staining of xenograft tumor tissues. Immunohistochemical staining of xenograft tumor tissues with the indicated antibodies. p21-, p27-, p57-, and Ki67 positive cells (brown staining) were quantified at x400 magnification (meansSEM;**, P < 0.01;***, P < 0.001 vs. control); scale bars, 10 um.

    Cancer Res 2014 74(23), 7090-102. (+)-JQ1 purchased from Selleck.

  • (D) Effect of JQ1 on alterations of actin cytoskeleton in VEGF-induced HUVECs. The cells were pretreated with DMSO or JQ1 (100 nM) for 6 h, and stimulated with VEGF (10 ng/mL) for 12 h. F-actin (red) and nuclei (blue) were stained with phalloidin and DAPI, respectively. Representative images from 3 independent experiments.

    Sci Rep, 2016, 6:23770.. (+)-JQ1 purchased from Selleck.

    Sensitivity of BEZ235-resistant cells to JQ-1 using the MTT assay.

    Oncotarget, 2016, 6(7):5134-46.. (+)-JQ1 purchased from Selleck.

  • B. Repressed MCC-3 xenograft tumor growth upon combined treatment with MLN0128 and JQ1. Tumor bearing mice were treated with MLN0128 or vehicle at 1 mg/kg/day by oral gavage and JQ1 or vehicle at 50 mg/kg/day by i.p. injection for a period of 30 days. C. A more effective reduction of MCC-3 xenograft tumor growth in the group treated with combined therapy. Fold-reduction of tumor growth was calculated as average tumor growth of control group divided by average tumor growth of treatment group. Tumor growth was calculated as final average tumor volume minus initial average tumor volume in each group.

    Oncotarget, 2016, 7(6):6576-92.. (+)-JQ1 purchased from Selleck.

    JQ1 induces cell cycle arrest and apoptosis in Cal27 cells. (C) Cal27 cells were treated with JQ1 for 24 h and whole cell lysates were tested by western blot assays for the expression of cleaved-caspase-3. GAPDH was used as a loading control. (D) Apoptosis of Cal27 cells treated with JQ1 at 0 and 0.5 µM JQ1; *P<0.05 vs. control (the DMSO group)

    Oncol Rep, 2016, 36(4):1989-96.. (+)-JQ1 purchased from Selleck.

  • Effect of BET domain family inhibition on AMI damage in cardiomyocytes. (A) LDH and (B) CK-MB activity in the serum. #P<0.01 vs. sham group; @P<0.05 and &P<0.01 vs. AMI group. BET, bromodomain and extra-terminal; AMI, acute myocardial infarction; LDH, lactate dehydrogenase; CK-MB, creatine kinase MB isoenzyme.

    Exp Ther Med, 2015, 10(6):2319-2324.. (+)-JQ1 purchased from Selleck.

Purity & Quality Control

Choose Selective Epigenetic Reader Domain Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description (+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2) in cell-free assays, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family.
Features (+)-JQ1 is more effective than (-)-JQ1.
Targets
BRD4 (2) [1]
(Cell-free assay)
BRD4 (1) [1]
(Cell-free assay)
33 nM 77 nM
In vitro

(+)-JQ1 enantiomer binds directly into the Kac binding site of BET bromodomains. (+)-JQ1 (500 nM) binds BRD4 competitively with chromatin resulting in differentiation and growth arrest of NMC cells. (+)-JQ1 (500 nM) attenuates rapid proliferation of NMC 797 and Per403 cell lines as demonstrated by reduced Ki67 staining. (+)-JQ1 (500 nM) potently decreases expression of both BRD4 target genes in NMC 797 cells. (+)-JQ1 inhibits cellular viability with IC50 of 4 nM in NMC 11060 cells. [1] (+)-JQ1 results in robust inhibition of MYC expression in MM cell lines. (+)-JQ1 inhibits proliferating of KMS-34 and LR5 with IC50 of 68 nM and 98 nM, respectively. (+)-JQ1 (500 nM)-treated MM.1S cells results in a pronounced decrease in the proportion of cells in S-phase, with a concomitant increase in cells arrested in G0/G1. (+)-JQ1 (500 nM) results in pronounced cellular senescence by beta-galactosidase staining. (+)-JQ1 (800 nM) exposure leads to a significant reduction in cell viability among the majority of CD138+ patient-derived MM samples tested. [2] (+)-JQ1 inhibits growth of LP-1 cells with GI50 of 98 nM. (+)-JQ1 (625 nM) results in an increase in the percentage of LP-1 cells in G0/G1. (+)-JQ1 (500 nM) suppresses the expression of MYC, BRD4 and CDK9 in LP-1 cells. [3] (+)-JQ1 (1 μM) activates HIV transcription in latently infected Jurkat T cells. (+)-JQ1 (50 μM) stimulates predominantly Tat-dependent HIV transcription in both Jurkat and HeLa cells. (+)-JQ1 (5 μM) induces Brd4 dissociation enables Tat to recruit SEC to HIV promoter and induce Pol II CTD phosphorylation and viral transcription in J-Lat A2 cells. JQ1 enables Tat to increase CDK9 T-loop phosphorylation and partially dissociates P-TEFb from 7SK snRNP in Jurkat T cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
K1  MlPWR4VtdCCYaXHibYxqfHliQYPzZZk> MmnrNlUxNzVyMD:xNFAxKG6P MXOyOE81QC95MjDo NE\q[nNFVVOR NUnxUmVNcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDDkc5NmNSCjbnSgeIlu\S1iZHXw[Y5l\W62IH3hco5meg>? MVGyOlcxPzh6MR?=
BCPAP M2TaNmNmdGxiVnnhZoltcXS7IFHzd4F6 NWrLcWU6OjVyL{WwNE8yODByIH7N M3;QZlI1NzR6L{eyJIg> NXvQXoFkTE2VTx?= NEK3OmJqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz NVHYTHNsOjZ5MEe4PFE>
K1  NVzMOZB5S2WubDDDfYNt\SCDc4PhfS=> Mlj6NlUxNzVyMD:xNFAxKG6P M4PKPVczKGh? M4DIdWROW09? NXG4OHJP[XK{ZYP0d{Bk\WyuIHP5Z4xmKGG2IFewM2cyKHCqYYPl Mn3QNlY4ODd6OEG=
BCPAP NIjRcXRE\WyuIFP5Z4xmKEG|c3H5 MknzNlUxNzVyMD:xNFAxKG6P M{jid|czKGh? M4PJXWROW09? M1PHfIFzemW|dIOgZ4VtdCCleXPs[UBifCCJMD;HNUBxcGG|ZR?= NYXEV|RJOjZ5MEe4PFE>
Hep3B NGPKbopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fueVAuOTBizszN MYm1JIQ> NEe4PHFFVVOR NGG3U5lKSzVyPUCuNFgh|ryP NFnBcFUzPjV5NUG2Oy=>
HCCLM3 M1faTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTE[mwyOC1zMDFOwG0> MVu1JIQ> Mm\uSG1UVw>? MlTiTWM2OD1yLkG0JO69VQ>? MmruNlY2PzVzNke=
HuH7 MnTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDPbHUxNTFyIN88US=> MkTHOUBl NYDFSpdYTE2VTx?= NUDKVG45UUN3ME2wMlIyKM7:TR?= MWSyOlU4PTF4Nx?=
HepG2 NHjwWlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnL1NE0yOCEQvF2= NFPWUWY2KGR? MmTSSG1UVw>? MX\JR|UxRTBwM{Sg{txO M2LrR|I3PTd3MU[3
SMMC7721 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXmwMVExKM7:TR?= NIG1RoQ2KGR? NGjmXYhFVVOR MUjJR|UxRTBwNEGg{txO MV:yOlU4PTF4Nx?=
BEL7402 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWmwMVExKM7:TR?= M37KPVUh\A>? M4HpSWROW09? M1rs[GlEPTB;MD60O{DPxE1? NVmzSY5VOjZ3N{WxOlc>
MHCC97H MmjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHaT5UxNTFyIN88US=> MU[1JIQ> NG\BVZZFVVOR NVnRUmNoUUN3ME2wMlQyKM7:TR?= NHjGWnAzPjV5NUG2Oy=>
Hep3B NHTrdIpE\WyuIFP5Z4xmKEG|c3H5 NFLsTVExNjFxMD61M|IvPSEQvF2= NGOxSWQ1QCCq M{O3RWROW09? MljkcIVi\HNidH:gZUB{fWK|dHHueIlidCCjY3P1cZVt[XSrb36gc4YhUEOFIHPlcIx{KGmwIIP1Zk1IOSCyaHHz[eKh MWSyOlU4PTF4Nx?=
HCCLM3 MlrYR4VtdCCFeXPs[UBCe3OjeR?= NWrNcYRlOC5zL{CuOU8zNjVizszN M1PhVFQ5KGh? NVXyfoljTE2VTx?= MXTs[YFleyC2bzDhJJN2[nO2YX70bYFtKGGlY4XteYxifGmxbjDv[kBJS0NiY3XscJMhcW5ic4XiMWcyKHCqYYPlxsA> MWGyOlU4PTF4Nx?=
Hep3B Ml3sRZBweHSxc3nzJGF{e2G7 Mli3NE4yNzBwNT:yMlUh|ryP NXzhZYVUPDhiaB?= MlvYSG1UVw>? M2rhfIFkfGm4YYTld{Bk[XOyYYPlMVMh[W6mIHPhd5Bie2VvOTDlfJBz\XO|aX;uJIFv\CCrbnT1Z4VlKFCDUmCgZ4xm[X[jZ3WgZZMhf2WubDDhd{BkgXSxY3jyc41mKGNicnXs[YF{\SCrboTvJJRp\SCleYTvdIxie21iZoLvcUBucXSxY3jvcoRzcWF? NHPRdXkzPjV5NUG2Oy=>
HCCLM3 MYfBdI9xfG:|aYOgRZN{[Xl? NWPCXnhiOC5zL{CuOU8zNjVizszN MXi0PEBp MkPpSG1UVw>? NXmxR4h1[WO2aY\heIV{KGOjc4Dhd4UuOyCjbnSgZ4F{eGG|ZT25JIV5eHKnc4Ppc44h[W6mIHnu[JVk\WRiUFHSVEBkdGWjdnHn[UBieyC5ZXzsJIF{KGO7dH;jbJJwdWViYzDy[Yxm[XOnIHnueI8hfGinIHP5eI9xdGG|bTDmdo9uKG2rdH;jbI9v\HKrYR?= NX;lWFFOOjZ3N{WxOlc>
A549 MoHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Ljc|AvOS1zMDFOwG0> NV3FRVY3PzJiaB?= MYfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NGDrdGczPjRzNUKyOS=>
H157 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPpNE4yNTFyIN88US=> NGjSSWE4OiCq MkXDbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M{XMblI3PDF3MkK1
H1299 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHYNE4yNTFyIN88US=> M2fwdlczKGh? M3\VeIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MkO0NlY1OTV{MkW=
A549 MoHwSpVv[3Srb36gRZN{[Xl? Mm\YNU8zNjVxNTFOwG0> MU[xNkBp NXzBR3lVyqC5ZXHrcJkh\GWlcnXhd4VlKEKlbD2yJIxmfmWucx?= M2S0SlI3PDF3MkK1
H1299 NET4XnNHfW6ldHnvckBCe3OjeR?= M2fxTVEwOi53L{Wg{txO MUexNkBp M3TyeuKhf2Wja3z5JIRm[3KnYYPl[EBD[2xvMjDs[ZZmdHN? NHXycVgzPjRzNUKyOS=>
H157 NEL6Ro5HfW6ldHnvckBCe3OjeR?= MWWxM|IvPS93IN88US=> NVXIdpRlOTJiaB?= Mo\6[IVkemWjc3XkJGRTPCCneIDy[ZN{cW:w NIHEdpAzPjRzNUKyOS=>
H1299 MVfGeY5kfGmxbjDBd5NigQ>? MVqxM|IvPS93IN88US=> MX[xNkBp MlHK[IVkemWjc3XkJGRTPCCneIDy[ZN{cW:w M{DxSVI3PDF3MkK1
C8161 M{TMUWNmdGxiVnnhZoltcXS7IFHzd4F6 M1XmdFAuOiEQvF2= NVSyOpJkPCCm M3HzUWROW09? NG\HXoll\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= Mlr5NlY{QTd{MkO=
Mel285 M2PPVmNmdGxiVnnhZoltcXS7IFHzd4F6 NEXKVnUxNTJizszN MWW0JIQ> MofXSG1UVw>? NFfZcGpl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= Mn;KNlY{QTd{MkO=
Mel290 NWD3boU1S2WubDDWbYFjcWyrdImgRZN{[Xl? M4nNXlAuOiEQvF2= MmX2OEBl M3\rZ2ROW09? MXTk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NEHWcGczPjN7N{KyNy=>
92.1 MWfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M4mzWlAuOiEQvF2= MlzpOEBl MnPISG1UVw>? NHzXZVVl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MoTSNlY{QTd{MkO=
Omm1.3 MnnlR4VtdCCYaXHibYxqfHliQYPzZZk> Mn;mNE0zKM7:TR?= M2TBRlQh\A>? NFixO4pFVVOR MkLD[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NFPVTngzPjN7N{KyNy=>
Mel202 NVjXZ5RDS2WubDDWbYFjcWyrdImgRZN{[Xl? NHf2O3IxNTJizszN MkfYOEBl M3HCR2ROW09? Ml\l[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MmDONlY{QTd{MkO=
Mel270 M3vr[WNmdGxiVnnhZoltcXS7IFHzd4F6 M{PnTFAuOiEQvF2= NX25dVNwPCCm MYXEUXNQ MlPR[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MoDhNlY{QTd{MkO=
Omm1 NXfMUW1bS2WubDDWbYFjcWyrdImgRZN{[Xl? MnzaNE0zKM7:TR?= MYK0JIQ> MoGxSG1UVw>? M1XJeIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MWiyOlM6PzJ{Mx?=
92.1 NX;zboNHSXCxcITvd4l{KEG|c3H5 Mmj1OVAxKG6P MWK0PEBp M2fzbWROW09? MlizbY5lfWOnczDhdI9xfG:|aYO= Ml7CNlY{QTd{MkO=
Omm1.3 NH3BZZJCeG:ydH;zbZMhSXO|YYm= Ml21OVAxKG6P M4HJVFQ5KGh? M{\ZSWROW09? M37BUIlv\HWlZYOgZZBweHSxc3nz NYL2fXQ3OjZ|OUeyNlM>
92.1 NEXufo9E\WyuIFP5Z4xmKEG|c3H5 NFvnfZE2ODBibl2= NFWxXJczPC92OD:3NkBp MYnEUXNQ M3zHZ4lv\HWlZYOgeIhmKGOnbHygZYNkfW23bHH0bY9vKGG2IIP1Zk1IOcLi MmnsNlY{QTd{MkO=
Omm1.3 MlzrR4VtdCCFeXPs[UBCe3OjeR?= M1TWcFUxOCCwTR?= Mof1NlQwPDhxN{KgbC=> M2PU[GROW09? NWnQT5RwcW6mdXPld{B1cGViY3XscEBi[2O3bYXsZZRqd25iYYSgd5VjNUdzwrC= NVnvVm9uOjZ|OUeyNlM>
A549 MX\GeY5kfGmxbjDBd5NigQ>? MV:xNFAwPDByL{GwNFAhdk1? NFnqO4UzPCCq MkXWeZBz\We3bHH0[ZMh[W6mIHHjeIl3[XSnczDTTXJVOQ>? MYSyOlIyOjF7OR?=
MCF-7 NIXpPZNHfW6ldHnvckBCe3OjeR?= MWKxNFAwPDByL{GwNFAhdk1? NH3HRZYzPCCq MWr1dJJm\3WuYYTld{BidmRiYXP0bZZifGW|IGPJVnQy MXeyOlIyOjF7OR?=
HEK293 NF;2fYhHfW6ldHnvckBCe3OjeR?= Ml62NVAxNzRyMD:xNFAxKG6P MnfMNlQhcA>? NVjuZo5[fXC{ZXf1cIF1\XNiYX7kJIFkfGm4YYTld{BUUVKWMR?= MV:yOlIyOjF7OR?=
858 NIfld2xE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NGLKbHkxNTFizszN MmLKOUBl NYKxVI56TE2VTx?= MoLj[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MU[yOlIxPjN|Mx?=
DDR2L63V NH\ueVdE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NWTtdFRFOC1zIN88US=> MUO1JIQ> NGLafnNFVVOR M4THUIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NHzDcpYzPjJyNkOzNy=>
BE(2)-C M3jlXmNmdGxiVnnhZoltcXS7IFHzd4F6 MVmxJO69VQ>? Ml\nNU01KGR? NHfhOGhl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>? NHPNbJEzPjB4N{S2OC=>
IMR-32 MnjJR4VtdCCYaXHibYxqfHliQYPzZZk> NH7Kb2wyKM7:TR?= NES0T4YyNTRiZB?= NWDmU3pp\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJNq\26rZnnjZY51dHl? MX[yOlA3PzR4NB?=
JF NXnPNWViS2WubDDWbYFjcWyrdImgRZN{[Xl? Mon6NUDPxE1? MkP5NU01KGR? MXrk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlic3nncolncWOjboTsfS=> M4PNc|I3ODZ5NE[0
BE(2)-M17 NWGwUlRGS2WubDDWbYFjcWyrdImgRZN{[Xl? NHHnc5MyKM7:TR?= MnHtNU01KGR? NIPjVGZl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>? NITQT5czPjB4N{S2OC=>
SK-N-SH MkfZR4VtdCCYaXHibYxqfHliQYPzZZk> MmqyNUDPxE1? MmP6NU01KGR? NIrrUHBl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>? NGfpdYkzPjB4N{S2OC=>
SK-N-DZ  M1vrVmNmdGxiVnnhZoltcXS7IFHzd4F6 MkjLNUDPxE1? Mn30NU01KGR? Mlfy[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIPp[45q\mmlYX70cJk> MXSyOlA3PzR4NB?=
HMC-1.1  NYfQXHYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1i5XlUuPTByMDDuUS=> MV20PEBp NFG5dHhFVVOR MmjwbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MXOyOlA2PTNyMx?=
HMC-1.2 NVPwTmZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVH0SY5{PS13MECwJI5O NXT6bIpQPDhiaB?= MmixSG1UVw>? NYXLSXJncW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M{P1WlI3ODV3M{Cz
ROSA KIT WT  MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPKU4pIPS13MECwJI5O M17jZVQ5KGh? NHn4To9FVVOR NFLhd5BqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M3K4V|I3ODV3M{Cz
ROSA KIT D816V NXLU[lU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV[1MVUxODBibl2= M{XrdVQ5KGh? M1ftWmROW09? NX;seZV2cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NWnEZlhsOjZyNUWzNFM>
HMC-1.1  M4i2fmFxd3C2b4Ppd{BCe3OjeR?= NH\3bXozODBvNUCwNEBvVQ>? Ml7mOFghcA>? M160XmROW09? NVLYWHNXcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NWHjXoY1OjZyNUWzNFM>
HMC-1.2 NFjzUZZCeG:ydH;zbZMhSXO|YYm= M3O5O|IxOC13MECwJI5O NX[zSIMxPDhiaB?= MWLEUXNQ M3POWIlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MWeyOlA2PTNyMx?=
ROSA KIT WT  NH;DT5FCeG:ydH;zbZMhSXO|YYm= MUeyNFAuPTByMDDuUS=> NGXBdYI1QCCq NV6yXGRNTE2VTx?= NHnSZ4lqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NXvpemZ5OjZyNUWzNFM>
ROSA KIT D816V M37L[mFxd3C2b4Ppd{BCe3OjeR?= M2LOe|IxOC13MECwJI5O NFe2Z4I1QCCq MV;EUXNQ M2TmR4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NVLGcYV1OjZyNUWzNFM>
494H MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zCS|czKGh? NXfxb49iTE2VTx?= NHLIO29KSzVyPUCuNVIzyrFyLkCwOEDPxE1? NWXURXViOjV7NES1OlY>
493H M3K0emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrETnJ2PzJiaB?= NGfSbmNFVVOR NHfBUYpKSzVyPUCuNFQ4yrFyLkCwPUDPxE1? MlLONlU6PDR3Nk[=
716H MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13CflczKGh? NXXkSWl[TE2VTx?= MWTJR|UxRTBwMkGyxtExNjB|NDFOwG0> NF7DcpozPTl2NEW2Oi=>
148I MoLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWe3NkBp MWnEUXNQ Moi4TWM2OD1yLkK4OOKyOC5yM{Wg{txO NEe3dHIzPTl2NEW2Oi=>
98Sc M4\vfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVe3NkBp NVXocW5rTE2VTx?= Ml7wTWM2OD1yLkGxOeKyOC5yMESg{txO M13nSVI2QTR2NU[2
89R MmnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHYO|IhcA>? Mki1SG1UVw>? NWrOU|F[UUN3ME2wMlEzPsLzMD6wNFMh|ryP M2rxSlI2QTR2NU[2
494L MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUm3NkBp MXXEUXNQ NFK1RVRKSzVyPUCuN|E4yrFyLkCxNkDPxE1? M1O0U|I2QTR2NU[2
493L M3v4R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXsO|IhcA>? MWrEUXNQ NHjycnlKSzVyPUCuNFUxyrFyLkCxNUDPxE1? NHyxTJgzPTl2NEW2Oi=>
148L M{D4c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofTO|IhcA>? NX7N[XRsTE2VTx?= M37sbWlEPTB;MD6xOFbDuTBwMEG3JO69VQ>? M1rROlI2QTR2NU[2
98L NV;1cHhOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4W0elczKGh? NF21UoNFVVOR NV;SOWVWUUN3ME2wMlMxQcLzMD6wNlkh|ryP M3fDPVI2QTR2NU[2
OS17 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPQZ4Q4OiCq NIj0SoJFVVOR NWPydG9TUUN3ME2wMlA4QcLzMD6wNFMh|ryP MU[yOVk1PDV4Nh?=
OS9 NGj6bWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnBXnF3PzJiaB?= MX3EUXNQ MlToTWM2OD1yLkSwOuKyOC5yMkig{txO NHnU[HUzPTl2NEW2Oi=>
MG63 M3fPfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYG3NkBp NI\YS4tFVVOR MWrJR|UxRTBwMUG0xtExNjB{NTFOwG0> NGfJUY0zPTl2NEW2Oi=>
SAOS2 M1rzU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnhNYF5PzJiaB?= NIrjUpNFVVOR M4P6V2lEPTB;MD6yNVfDuTBwMECzJO69VQ>? NIGyUmEzPTl2NEW2Oi=>
U2OS M325WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvVO|IhcA>? M2DKdmROW09? Ml3FTWM2OD1yLkG5POKyOC5yMEig{txO MWeyOVk1PDV4Nh?=
SJSA-1 NUK4fnlxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrPO|IhcA>? M2rzZWROW09? NEjrfG1KSzVyPUCuNVAxyrFyLkCxNEDPxE1? MXOyOVk1PDV4Nh?=
494H NUjDXIplSXCxcITvd4l{KEG|c3H5 MUOwMlI2NzBwNT:xMlAh|ryP NV;KbWhSOjRiaB?= M1PFV2ROW09? NXjLS4xucW6lcnXhd4V{KGyndnXsd{Bw\iClbHXheoVlKGOjc4Dhd4UuO8Li MWmyOVk1PDV4Nh?=
148I MmfVRZBweHSxc3nzJGF{e2G7 MmTRNE4zPS9yLkWvNU4xKM7:TR?= NX61UXI3OjRiaB?= NFj3bJBFVVOR NXu1dVZlcW6lcnXhd4V{KGyndnXsd{Bw\iClbHXheoVlKGOjc4Dhd4UuO8Li MUCyOVk1PDV4Nh?=
OS17 MYDBdI9xfG:|aYOgRZN{[Xl? MUOwMlI2NzBwNT:xMlAh|ryP NWr1UIp2OjRiaB?= MUXEUXNQ MYTpcoNz\WG|ZYOgcIV3\Wy|IH;mJINt\WG4ZXSgZ4F{eGG|ZT2zxsA> NUnW[o9LOjV7NES1OlY>
494H Mlu3RZBweHSxc3nzJGF{e2G7 M3vnSVHjiIoQvF2= NYjx[VJCPDhiaB?= NVTXfVB{TE2VTx?= M3myZ4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3nncolncWOjboTsfS=> M3T1fVI2QTR2NU[2
148I NUj4Tot4SXCxcITvd4l{KEG|c3H5 M2fGZ|HjiIoQvF2= MYW0PEBp NUjucJI1TE2VTx?= MWPpcoR2[2W|IHPlcIwh[XCxcITvd4l{KHOrZ37p[olk[W62bIm= MoK0NlU6PDR3Nk[=
OS17 NG\GVpVCeG:ydH;zbZMhSXO|YYm= NWLae4xXOeLCid88US=> M4\TblQ5KGh? NEHvOG1FVVOR MnzJbY5lfWOnczDj[YxtKGGyb4D0c5NqeyC|aXfubYZq[2GwdHz5 Mk\ENlU6PDR3Nk[=
MOLM13 MnmyRZBweHSxc3nzJGF{e2G7 NVLYPZM4OjVyIH7N MYm0PEBp MVvEUXNQ NFT2UJJqdmS3Y3XzJJNq\26rZnnjZY51dHliYYDvdJRwe2m|IHPveJJm[XSvZX70JJdqfGhicYXpfoFzfGmwaXK= NFPhXVkzPTB3M{iyOS=>
MV4-11  MojrRZBweHSxc3nzJGF{e2G7 NXrpNotSOjVyIH7N MX:0PEBp MknQSG1UVw>? NFjKSZdqdmS3Y3XzJJNq\26rZnnjZY51dHliYYDvdJRwe2m|IHPveJJm[XSvZX70JJdqfGhicYXpfoFzfGmwaXK= Mlv4NlUxPTN6MkW=
MOLM13 NIrRRYFHfW6ldHnvckBCe3OjeR?= MXSyOVAhdk1? MojJNlQhcA>? MmfnSG1UVw>? NFW5WpFmdmijbnPld{ByfWm8YYL0bY5q[i2rbnT1Z4VlKG2xcnWgdFIyNCCESV2sJIFv\CClbHXheoVlKFCDUmC= MmC4NlUxPTN6MkW=
MV4-11  NYq4UnhDTnWwY4Tpc44hSXO|YYm= NYfsWFhYOjVyIH7N MVSyOEBp NHvnVmpFVVOR M1PSSoVvcGGwY3XzJJF2cXqjcoTpcoljNWmwZIXj[YQhdW:{ZTDwNlEtKEKLTTygZY5lKGOuZXH2[YQhWEGUUB?= NUDibZpQOjVyNUO4NlU>
MOLM13 M3jmeWFxd3C2b4Ppd{BCe3OjeR?= MWCyOVAhdk1? Mny2OFghcA>? M3fw[WROW09? NFnBWItqdmS3Y3XzJJNq\26rZnnjZY51dHliYYDvdJRwe2m|IHPveJJm[XSvZX70JJdqfGhicH;uZZRqdmmk NITRd2YzPTB3M{iyOS=>
MV4-11  M2K5OmFxd3C2b4Ppd{BCe3OjeR?= MVOyOVAhdk1? MVq0PEBp M1zGbWROW09? M{PLPYlv\HWlZYOgd4lodmmoaXPhcpRtgSCjcH;weI9{cXNiY3;0doVifG2nboSge4l1cCCyb37heIlvcWJ? NXjKT4d4OjVyNUO4NlU>
Hela MVPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NWTlWpJ5OC13MECgcm0> M2PrNFczKGh? MkX6SG1UVw>? M3\JT4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MVGyOVAxQTJ7NR?=
HBL-1 MYXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NWGzdGRJOC13MECgcm0> NHPSWI84OiCq MUjEUXNQ NEP1XlJl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NWXRS|RuOjVyMEmyPVU>
HLY-1 MlzZR4VtdCCYaXHibYxqfHliQYPzZZk> MoPlNE02ODBibl2= NEi1bY04OiCq M3e4fGROW09? MkXo[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MWOyOVAxQTJ7NR?=
OCI-Ly3 NEn4[YRE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MkK3NE02ODBibl2= NHyy[ng4OiCq MUHEUXNQ NVroZ|Z5\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M3X5e|I2ODB7Mkm1
OCI-Ly10 NYD6UYs2S2WubDDWbYFjcWyrdImgRZN{[Xl? M1LQdVAuPTByIH7N MYW3NkBp NE\4U2VFVVOR M2rZUIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MVqyOVAxQTJ7NR?=
SU-DHL-4 NXnMVItqS2WubDDWbYFjcWyrdImgRZN{[Xl? M2\XdFAuPTByIH7N MnfzO|IhcA>? NX3ObZNITE2VTx?= MY\k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NX;WOnd6OjVyMEmyPVU>
SU-DHL-5 MVTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M1XiO|AuPTByIH7N NVyzNJVNPzJiaB?= NXvPcpRiTE2VTx?= NF22VXll\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NGmybpkzPTByOUK5OS=>
SU-DHL-6 NU\mdY8yS2WubDDWbYFjcWyrdImgRZN{[Xl? NV\NZWdTOC13MECgcm0> NGfqNII4OiCq M2HQRWROW09? MoTN[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NYrBZ2YzOjVyMEmyPVU>
SU-DHL-10 MWHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MnLwNE02ODBibl2= MXy3NkBp MY\EUXNQ M1riNYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NHvDbXozPTByOUK5OS=>
RC-K8 M{jDOmNmdGxiVnnhZoltcXS7IFHzd4F6 MnyzNE02ODBibl2= NFniT5o4OiCq NVXZUGN7TE2VTx?= M3:3[IRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M2P0dFI2ODB7Mkm1
OCI-Ly8 MWHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NWPMbVlbOC13MECgcm0> MVO3NkBp NYXSR4RDTE2VTx?= M1XH[oRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NYXofmJNOjVyMEmyPVU>
OCL-Ly18 Mlj0R4VtdCCYaXHibYxqfHliQYPzZZk> MUGwMVUxOCCwTR?= NFjiW3Q4OiCq Mm\XSG1UVw>? NGfqU2Jl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MnrUNlUxODl{OUW=
OCI-Ly3 MmXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\EUVE4Oi9{NUCvOVAxKG6P MlLmNk84KGR? MYHEUXNQ NYmzV4VocW6mdXPld{Bk\WyuLXP5Z4xmKGG{cnXzeEBifCC|dXKtS|Ehf2m2aDDtbY5qdWGuIHPlcIwh\GWjdHlCpC=> NEnme24zPTByOUK5OS=>
OCI-Ly8 MnP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3XT2tvOTd{L{K1NE82ODBibl2= MY[yM|ch\A>? MYLEUXNQ NXzGT4pxcW6mdXPld{Bk\WyuLXP5Z4xmKGG{cnXzeEBifCC|dXKtS|Ehf2m2aDDtbY5qdWGuIHPlcIwh\GWjdHlCpC=> NX3Kc21[OjVyMEmyPVU>
SU-DHL-4 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLWNVczNzJ3MD:1NFAhdk1? M3nNbVIwPyCm MnjhSG1UVw>? MnjWbY5lfWOnczDj[YxtNWO7Y3zlJIFzemW|dDDheEB{fWJvR{Gge4l1cCCvaX7pcYFtKGOnbHyg[IVifGkEoB?= Mly4NlUxODl{OUW=
SU-DHL-10 M3rj[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPaNVJEOTd{L{K1NE82ODBibl2= MYKyM|ch\A>? NV\RPYhLTE2VTx?= M4TCdIlv\HWlZYOgZ4VtdC2leXPs[UBienKnc4SgZZQhe3WkLVexJJdqfGhibXnubY1idCClZXzsJIRm[XSqwrC= MmDWNlUxODl{OUW=
OCI-Ly3 M3\lZWFxd3C2b4Ppd{BCe3OjeR?= NGTtZZYyPzJxMkWwJI5O M{jOSldl MmLvSG1UVw>? MlTIbY5kemWjc3XzJINie3Cjc3WtN{84KGGldHn2bZR6yqC|aXfubYZq[2GwdHz5 NGrkOI4zPTByOUK5OS=>
OCI-Ly8 MoDTRZBweHSxc3nzJGF{e2G7 MljRNVczNzJ3MDDuUS=> NVG5[nBkP2R? NEWxO4JFVVOR Ml3TbY5kemWjc3XzJINie3Cjc3WtN{84KGGldHn2bZR6yqC|aXfubYZq[2GwdHz5 MmjYNlUxODl{OUW=
SU-DHL-4 M{jxe2Fxd3C2b4Ppd{BCe3OjeR?= MY[xO|IwOjVyIH7N MUm3[C=> M2XHe2ROW09? MmPwbY5kemWjc3XzJINie3Cjc3WtN{84KGGldHn2bZR6yqC|aXfubYZq[2GwdHz5 M1XtRVI2ODB7Mkm1
SU-DHL-10 M2XXWWFxd3C2b4Ppd{BCe3OjeR?= M3XvXVE4Oi9{NUCgcm0> MmnoO4Q> MVzEUXNQ Mn25bY5kemWjc3XzJINie3Cjc3WtN{84KGGldHn2bZR6yqC|aXfubYZq[2GwdHz5 NITj[ZozPTByOUK5OS=>

... Click to View More Cell Line Experimental Data

In vivo (+)-JQ1 (50 mg/kg) inhibits tumors growth in mice with NMC 797 xenografts. (+)-JQ1 (50 mg/kg) results in effacement of NUT nuclear speckles in mice with NMC 797 xenografts, consistent with competitive binding to nuclear chromatin. (+)-JQ1 (50 mg/kg) induces strong (grade 31) keratin expression in NMC 797 xenografts. (+)-JQ1 (50 mg/kg) promotes differentiation, tumor regression and prolonged survival in mice models of NMC xenografts. [1] (+)-JQ1 (50 mg/kg) results in a significant prolongation in overall survival of SCID-beige mice orthotopically xenografted after intravenous injection with MM.1S-luc+ cells compared to vehicle-treated animals. [2] (+)-JQ1 (50 mg/kg i.p.) leads to a highly significant increase in survival of mice bearing Raji xenografts. [3]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: MC 11060 cells
  • Concentrations: ~500 nM
  • Incubation Time: 48 hours
  • Method:

    Cells are seeded into white, 384-well microtiter plates at 500 cells per well in a total volume of 50 μL media. The 797, TT and TE10 cells are grown in DMEM containing 1% penicillin/streptomycin and 10% FBS. The Per403 cells are grown in DMEM containing 1 % penicillin/streptomycin and 20% FBS. Patient-derived NMC 11060 cells are grown in RPMI with 10% FBS and 1% penicillin/streptomycin. (+)-JQ1 is delivered to microtiter assay plates by robotic pin transfer. Following a 48 hours incubation at 37℃, cells are lysed and wells are assessed for total ATP content using a commercial proliferation assay. Replicate measurements are analyzed with respect to dose and estimates of IC50 are calculated by logistic regression (GraphPad Prism).


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Mice bearing NMC 797 xenografts
  • Formulation: 5% DMSO in 5% dextrose
  • Dosages: 50 mg/kg
  • Administration: intraperitoneal injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 91 mg/mL warmed (199.12 mM)
Ethanol 91 mg/mL (199.12 mM)
Water <1 mg/mL
In vivo 2% DMSO+30% PEG 300+5% Tween 80+ddH2O 5mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 456.99
Formula

C23H25ClN4O2S

CAS No. 1268524-70-4
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Epigenetic Reader Domain Signaling Pathway Map

Epigenetic Reader Domain Inhibitors with Unique Features

Tags: buy (+)-JQ1 | (+)-JQ1 supplier | purchase (+)-JQ1 | (+)-JQ1 cost | (+)-JQ1 manufacturer | order (+)-JQ1 | (+)-JQ1 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID